Literature DB >> 15913868

CANTAB explicit memory is less impaired in addicted schizophrenia patients.

Stéphane Potvin1, Catherine Briand, Antoinette Prouteau, Roch-Hugo Bouchard, Olivier Lipp, Pierre Lalonde, Luc Nicole, Alain Lesage, Emmanuel Stip.   

Abstract

It has been suggested that in order to sustain the lifestyle of substance abuse, addicted schizophrenia patients would have less negative symptoms, better social skills, and less cognitive impairments. Mounting evidence supports the first two assumptions, but data lack regarding cognition in dual diagnosis schizophrenia. Seventy-six schizophrenia outpatients (DSM-IV) were divided into two groups: with (n = 44) and without (n = 32) a substance use disorder. Motor speed and visuo-spatial explicit memory were investigated using CANTAB. As expected, dual diagnosis patients showed a better cognitive performance. Our results suggest either that substance abuse relieves the cognitive deficits of schizophrenia or that the patients with less cognitive deficits are more prone to substance abuse.

Entities:  

Mesh:

Year:  2005        PMID: 15913868     DOI: 10.1016/j.bandc.2005.04.002

Source DB:  PubMed          Journal:  Brain Cogn        ISSN: 0278-2626            Impact factor:   2.310


  17 in total

1.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

2.  Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.

Authors:  Rachel A Rabin; Mera S Barr; Michelle S Goodman; Yarissa Herman; Konstantine K Zakzanis; Stephen J Kish; Michael Kiang; Gary Remington; Tony P George
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

3.  Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Authors:  Thomas Wobrock; Helmut Sittinger; Bernd Behrendt; Roberto D'Amelio; Peter Falkai; Dieter Caspari
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-11-25       Impact factor: 5.270

4.  The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample.

Authors:  Murat Yücel; Emre Bora; Dan I Lubman; Nadia Solowij; Warrick J Brewer; Sue M Cotton; Philippe Conus; Michael J Takagi; Alex Fornito; Stephen J Wood; Patrick D McGorry; Christos Pantelis
Journal:  Schizophr Bull       Date:  2010-07-25       Impact factor: 9.306

5.  Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.

Authors:  Ana M Sánchez-Torres; Virginia Basterra; Araceli Rosa; Lourdes Fañanás; Amalia Zarzuela; Berta Ibáñez; Víctor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-12       Impact factor: 5.270

6.  Predictors of community functioning in schizophrenia and substance use disorder patients.

Authors:  Simon Zhornitsky; Ginette Aubin; Joelle Desfossés; Elie Rizkallah; Tania Pampoulova; Olivier Lipp; Jean-Pierre Chiasson; Emmanuel Stip; Stéphane Potvin
Journal:  Community Ment Health J       Date:  2012-07-31

7.  Effects of early psychosocial deprivation on the development of memory and executive function.

Authors:  Karen J Bos; Nathan Fox; Charles H Zeanah; Charles A Nelson Iii
Journal:  Front Behav Neurosci       Date:  2009-09-01       Impact factor: 3.558

8.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

9.  Visual memory of meaningless shapes in children and adolescents with autism spectrum disorders.

Authors:  Maryam Salmanian; Mehdi Tehrani-Doost; Maria Ghanbari-Motlagh; Zahra Shahrivar
Journal:  Iran J Psychiatry       Date:  2012

10.  Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia.

Authors:  K A Gleason; S G Birnbaum; A Shukla; S Ghose
Journal:  Transl Psychiatry       Date:  2012-11-27       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.